Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus

Objective. To analyse prospectively the diagnostic sensitivity and specificity as well as the clinical relevance of ribosomal P (anti-P) autoantibodies in a large cohort of SLE patients. Methods. The anti-P autoantibodies were evaluated in the serum of 200 Tunisian SLE patients at disease onset and...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2009-08, Vol.48 (8), p.953-957
Main Authors: Haddouk, Samy, Marzouk, Sameh, Jallouli, Moez, Fourati, Hajer, Frigui, Makram, Hmida, Youssef B. H., Koubaa, Faten, Sellami, Wassim, Baklouti, Sofiene, Hachicha, Jamil, Bahloul, Zouheir, Masmoudi, Hatem
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anti-ribosomal P antibodies
Antibodies, Anticardiolipin - blood
Arthritis - complications
Arthritis - immunology
Autoantibodies - blood
Biological and medical sciences
Biomarkers - blood
Case-Control Studies
Chi-Square Distribution
Clinical associations
Diseases of the osteoarticular system
Female
Humans
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - immunology
Male
Medical sciences
Middle Aged
Odds Ratio
Prognosis
Prospective Studies
Ribosomal Proteins - immunology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Sensitivity
Sensitivity and Specificity
Specificity
Systemic lupus erythematosus
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To analyse prospectively the diagnostic sensitivity and specificity as well as the clinical relevance of ribosomal P (anti-P) autoantibodies in a large cohort of SLE patients. Methods. The anti-P autoantibodies were evaluated in the serum of 200 Tunisian SLE patients at disease onset and 130 various control subjects by a sensitive immunodot assay. A complete laboratory evaluation and clinical examination were performed in each SLE patient. During the follow-up, the patients were regularly monitored for clinical parameters. Global SLE activity was measured by the ECLAM. Results. The sensitivity and specificity of anti-P testing for SLE were 23.5 and 98.4%, respectively. The anti-P-positive samples 14/47 (29.8%), 27/47 (57.4%) and 5/47 (10.6%) were negative for anti-dsDNA, anti-Sm or both antibodies, respectively. The anti-P-positive patients showed more active disease activity and a much higher prevalence of arthritis. An association between IgG aCLs and anti-P antibodies was also found. However, anti-P antibodies were not associated with neuropsychiatric manifestations or lupus nephritis. Conclusion. This study does not seem to confirm the described association of anti-P antibodies with neuropsychiatric manifestations of SLE. However, it supports the anti-P antibody association with arthritis and disease activity as well as the presence of aCL. Based on our study and other related studies, we propose that, akin to anti-Sm and anti-dsDNA, anti-P antibodies detected by one agreed method may be considered for inclusion as a criterion for the classification of SLE.
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kep142